Andrew D. Dickinson, the Chief Financial Officer of Gilead Sciences, Inc. (NASDAQ:GILD), a prominent biotechnology company with a market capitalization of $113 billion and "GREAT" financial health ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Salesforce, Inc. (CRM), Shell plc ...

We recently published a list of 15 Best NASDAQ Dividend Stocks To Buy. In this article, we are going to take a look at where ...

Gilead Sciences reached a settlement with the Justice Department and HHS that resolves a five-year legal dispute regarding patents for its HIV prevention drugs, Truvada and Descovy.

Gilead Sciences Inc. and the federal government settled a patent-infringement case in which the US sought $1 billion from the ...

Below, check out the roundup of California Healthline’s coverage. For today's national health news, read KFF Health News’ Morning Briefing.

Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and ...

Kite Pharma is flying high with the addition of a new member to its senior leadership team. | Kite Pharma is flying high with ...

Jefferies analyst Michael Yee maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

In multiple healthcare developments, Democratic states aim to safeguard Biden's rule for DACA immigrants, while ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Lyell Immunopharma (LYEL – Research Report) ...

After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a ...